Mr. Pimplaskar brings 25 years of experience in CMC, pharmaceutical development, clinical manufacturing and technology transfer to his role as head of CMC for global drug development of Milestone’s cardiovascular programs. Prior to assuming the leadership role in 2018, he served Milestone as a CMC consultant. Mr. Pimplaskar was formerly the executive director, CMC and pharmaceutical development for Axsome Therapeutics Inc. (Nasdaq: AXSM), where he led Axsome’s pharmaceutical development and clinical manufacturing projects across all research and development programs. Before joining Axsome, Mr. Pimplaskar led the CMC efforts of Chelsea Therapeutics (Nasdaq: CHTP) and played a pivotal role in the company’s successful NDA filing for Northera, a drug for the treatment of Neurogenic Orthostatic Hypotension. The drug earned FDA approval in 2014, after which the company was purchased by Lundbeck.
Throughout his career, Mr. Pimplaskar has served in progressively senior positions at leading industry innovators, including Upsher-Smith Laboratories, Bristol Myers Squibb Company (NYSE: BMY), and Pfizer Consumer Health (NYSE: PFE). His roles have encompassed pharmaceutical development (including formulation development), analytical development and clinical manufacturing. He is an active member of the American Association of Pharmaceutical Scientists (AAPS) and a charter member of the AAPS Nasal Drug Delivery Focus Group. He has co-authored several publications and conference presentations, and an inventor in several patents in the area of nasal and topical drug delivery.
Mr. Pimplaskar is an alumnus of the University of Rhode Island, where he earned an M.S. in Pharmaceutics. He also holds an MBA from Averett University and a Bachelor’s in Pharmacy from the University of Pune.